The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1295
September 22, 2008
View Complete Issue         Table of Contents 2019 
Issue 1295
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Clevidipine (Cleviprex) for IV Treatment of Severe Hypertension
September 22, 2008 (Issue: 1295)
Clevidipine (Cleviprex - The Medicines Company), a dihydropyridine calcium channel blocker (CCB), has been approved by the FDA for intravenous (IV) use in lowering high blood pressure. It is the second IV CCB to be marketed in the US; nicardipine has...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1295
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.